Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis

An open-label, phase II study demonstrated that a ruxolitinib dose-escalation approach (10 mg BID plus incremental increases of 5 mg BID at weeks 12 and 18, up to 20 mg BID) may help reduce the severity of anemia among patients with myelofibrosis.

Oncology Nurse Advisor